Sight Sciences prelim Q4 2024 rev $18.9-19.1M (+1% YoY); Surgical Glaucoma +9%

Sight Sciences, Inc.

2024-FY EPS reported -$1.03 revenue$79,866,000

Surgical Glaucoma revenue $18.7-18.8M (+9% YoY at midpoint); Dry Eye rev $0.2-0.3M vs $1.6M prior year.
Full year 2024 total revenue $79.7-79.9M (-2% YoY); cash and equivalents ~$120M; $1.4M generated in Q4.
New LCDs by five Medicare contractors effective mid-November restricted MIGS coverage, impacting results.
Company plans to achieve cash flow breakeven without additional equity capital; FY 2024 cash used $18.1M down from $46.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.